These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
85 related articles for article (PubMed ID: 17629779)
1. Potential effects of angiotensin II receptor blockers on glucose tolerance and adiponectin levels in hypertensive patients. Makita S; Abiko A; Naganuma Y; Moriai Y; Nakamura M Cardiovasc Drugs Ther; 2007 Aug; 21(4):317-8. PubMed ID: 17629779 [No Abstract] [Full Text] [Related]
2. Does the PPAR-γ-activating property of telmisartan provide a benefit in clinical practice? Fujimura A; Ushijima K; Ando H Hypertens Res; 2013 Feb; 36(2):183. PubMed ID: 23190691 [No Abstract] [Full Text] [Related]
5. Effects of telmisartan on insulin resistance in Japanese type 2 diabetic patients. Watanabe M; Inukai K; Sumita T; Ikebukuro K; Ito D; Kurihara S; Ono H; Awata T; Katayama S Intern Med; 2010; 49(17):1843-7. PubMed ID: 20823643 [TBL] [Abstract][Full Text] [Related]
6. Telmisartan treatment decreases visceral fat accumulation and improves serum levels of adiponectin and vascular inflammation markers in Japanese hypertensive patients. Chujo D; Yagi K; Asano A; Muramoto H; Sakai S; Ohnishi A; Shintaku-Kubota M; Mabuchi H; Yamagishi M; Kobayashi J Hypertens Res; 2007 Dec; 30(12):1205-10. PubMed ID: 18344626 [TBL] [Abstract][Full Text] [Related]
7. Prophylactic treatment with telmisartan induces tissue-specific gene modulation favoring normal glucose homeostasis in Cohen-Rosenthal diabetic hypertensive rats. Younis F; Oron Y; Limor R; Stern N; Rosenthal T Metabolism; 2012 Feb; 61(2):164-74. PubMed ID: 21820685 [TBL] [Abstract][Full Text] [Related]
8. Telmisartan in the treatment of Cohen-Rosenthal Diabetic Hypertensive rats: the benefit of PPAR-gamma agonism. Younis F; Kariv N; Nachman R; Zangen S; Rosenthal T Clin Exp Hypertens; 2007 Aug; 29(6):419-26. PubMed ID: 17729058 [TBL] [Abstract][Full Text] [Related]
9. Alterations of insulin resistance and the serum adiponectin level in patients with type 2 diabetes mellitus under the usual antihypertensive dosage of telmisartan treatment. Fuke Y; Fujita T; Satomura A; Wada Y; Matsumoto K Diabetes Technol Ther; 2010 May; 12(5):393-8. PubMed ID: 20388049 [TBL] [Abstract][Full Text] [Related]
10. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property. Yamagishi S; Takeuchi M Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852 [TBL] [Abstract][Full Text] [Related]
12. The effects of telmisartan and amlodipine on metabolic parameters and blood pressure in type 2 diabetic, hypertensive patients. Negro R; Hassan H J Renin Angiotensin Aldosterone Syst; 2006 Dec; 7(4):243-6. PubMed ID: 17318795 [TBL] [Abstract][Full Text] [Related]
13. Impact of the therapy by renin-angiotensin system targeting antihypertensive agents perindopril versus telmisartan on prothrombotic state in essential hypertension. Remková A; Kratochvíl'ová H; Durina J J Hum Hypertens; 2008 May; 22(5):338-45. PubMed ID: 18305548 [TBL] [Abstract][Full Text] [Related]
14. Vascular protection in diabetes: a pharmacological view of angiotensin II type 1 receptor blockers. Kintscher U; Unger T Acta Diabetol; 2005 Apr; 42 Suppl 1():S26-32. PubMed ID: 15868116 [TBL] [Abstract][Full Text] [Related]
15. Relative effects of telmisartan, candesartan and losartan on alleviating arterial stiffness in patients with hypertension complicated by diabetes mellitus: an evaluation using the cardio-ankle vascular index (CAVI). Uehara G; Takeda H J Int Med Res; 2008; 36(5):1094-102. PubMed ID: 18831906 [TBL] [Abstract][Full Text] [Related]
16. New treatment strategies for patients with hypertension and insulin resistance. Kurtz TW Am J Med; 2006 May; 119(5 Suppl 1):S24-30. PubMed ID: 16563944 [TBL] [Abstract][Full Text] [Related]
17. Influence of telmisartan on insulin response after glucose loading in obese patients with hypertension: ARB trial of hypertension in obese patients with hyperinsulinemia assessed by oral glucose tolerance test (ATHLETE). Mori Y; Tanaka T; Matsuura K; Yokoyama J; Utsunomiya K Adv Ther; 2011 Aug; 28(8):698-706. PubMed ID: 21744143 [TBL] [Abstract][Full Text] [Related]
18. [In the DETAIL. Kidney protection in manifestations of microalbuminuria]. MMW Fortschr Med; 2006 Jun; 148(26):51. PubMed ID: 16875382 [No Abstract] [Full Text] [Related]
19. Antihypertensive and metabolic effects of telmisartan in hypertensive HIV-positive patients. Vecchiet J; Ucciferri C; Falasca K; Mancino P; Di Iorio A; De Caterina R Antivir Ther; 2011; 16(5):639-45. PubMed ID: 21817185 [TBL] [Abstract][Full Text] [Related]
20. Metabolic actions of angiotensin receptor antagonists: PPAR-gamma agonist actions or a class effect? Ernsberger P; Koletsky RJ Curr Opin Pharmacol; 2007 Apr; 7(2):140-5. PubMed ID: 17303473 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]